TY - JOUR T1 - Transcriptomic Similarities and Differences in Host Response between SARS-CoV-2 and Other Viral Infections JF - medRxiv DO - 10.1101/2020.06.18.20131326 SP - 2020.06.18.20131326 AU - Simone A. Thair AU - Yudong D. He AU - Yehudit Hasin-Brumshtein AU - Suraj Sakaram AU - Rushika Pandya AU - Jiaying Toh AU - David Rawling AU - Melissa Remmel AU - Sabrina Coyle AU - George N. Dalekos AU - Ioannis Koutsodimitropoulos AU - Glykeria Vlachogianni AU - Eleni Gkeka AU - Eleni Karakike AU - Georgia Damoraki AU - Nikolaos Antonakos AU - Purvesh Khatri AU - Evangelos J Giamarellos-Bourboulis AU - Timothy E Sweeney Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/06/21/2020.06.18.20131326.abstract N2 - COVID-19 is a pandemic that shares certain clinical characteristics with other acute viral infections. Here, we studied the whole-blood transcriptomic host response to SARS-CoV-2 and compared it with other viral infections to understand similarities and differences in host response. Using RNAseq we profiled peripheral blood from 24 healthy controls and 62 prospectively enrolled patients with community-acquired lower respiratory tract infection by SARS-Cov-2 within the first 24 hours of hospital admission. We also compiled and curated 23 independent studies that profiled 1,855 blood samples from patients with one of six viruses (influenza, RSV, HRV, ebola, Dengue, and SARS-CoV-1). We show gene expression changes in peripheral blood in patients with COVID-19 versus healthy controls are highly correlated with changes in response to other viral infections (r=0.74, p<0.001). However, two genes, ACO1 and ATL3, show significantly opposite changes between conditions. Pathway analysis in patients with COVID-19 or other viral infections versus healthy controls identified similar pathways including neutrophil activation, innate immune response, immune response to viral infection, and cytokine production for over-expressed genes. Conversely, for under-expressed genes, pathways indicated repression of lymphocyte differentiation and T cell activation. When comparing transcriptome profiles of patients with COVID-19 directly with those with other viral infections, we found 114 and 302 genes were over- or under-expressed, respectively, during COVID-19. Pathways analysis did not identify any significant pathways in these genes, suggesting novel responses to further study. Statistical deconvolution using immunoStates found that M1 macrophages, plasmacytoid dendritic cells, CD14+ monocytes, CD4+ T cells, and total B cells showed change consistently in the same direction across all viral infections including COVID-19. Those that increased in COVID-19 but decreased in non-COVID-19 viral infections were CD56bright NK cells, M2 macrophages, and total NK cells. The concordant and discordant responses mapped out here provide a window to explore the pathophysiology of COVID-19 versus other viral infections and show clear differences in signaling pathways and cellularity as part of the host response to SARS-CoV-2.Competing Interest StatementSAT, YDH, YH, SS, RP, DR, MR, SC, and TES are employees of, and stockholders in, Inflammatix, Inc. PK is a shareholder and a consultant to Inflammatix, Inc. EJGB has received honoraria from AbbVie USA, Abbott CH, InflaRx GmbH, MSD Greece, XBiotech Inc. and Angelini Italy; independent educational grants from AbbVie, Abbott, Astellas Pharma Europe, AxisShield, bioMerieux Inc, InflaRx GmbH, and XBiotech Inc; and funding from the FrameWork 7 program HemoSpec (granted to the National and Kapodistrian University of Athens), the Horizon2020 Marie-Curie Project European Sepsis Academy (granted to the National and Kapodistrian University of Athens), and the Horizon 2020 European Grant ImmunoSep (granted to the Hellenic Institute for the Study of Sepsis). The other authors declare no competing interests.Clinical TrialThis was a non-interventional observational study.Funding StatementThis study was funded by Inflammatix, Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:COVID-19 samples: A total of 76 adult patients with SARS-CoV-2 pneumonia were prospectively enrolled from April 1st to May 4th by department participating in the Hellenic Sepsis Study Group (www.sepsis.gr). The studies were conducted under the 78/17 approval of the National Ethics Committee of Greece; the 23/12.08.2019 approval of the Ethics Committee of Sotiria Athens General Hospital; and the 26.02.2019 approval of the Ethics Committee of ATTIKON University General Hospital. Written informed consent was pro- vided by patients or by first-degree relatives in case of patients unable to consent. Blood RNA tubes were prospectively collected from healthy controls (HC) through a commercial vendor (BioIVT) under IRB approval (Western IRB #2016165) using informed consent. Patients were non-febrile and verbally screened to confirm that no signs or symptoms of infection were present within 3 days prior to sample collection and that they were not currently undergoing antibiotic treatment, nor had not taken antibiotics within 3 days prior to sample collection. Furthermore, all samples were negative for HIV, West Nile, Hepatitis B, and Hepatitis C by molecular or antibody-based testing.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe publicly available cohorts are available under their respective study IDs within the manuscript. The COVID-19 cohort has been deposited in GEO for public reuse (GSE152641). ER -